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ABSTRACT
Individualizing adjuvant chemotherapy is important in patients with advanced 
colorectal cancers (CRCs), and the ability to identify molecular subtypes predictive of 
good prognosis for stage III CRCs after adjuvant chemotherapy could be highly beneficial. 
We performed microarray-based gene expression analysis on 101 fresh-frozen primary 
samples from patients with stage III CRCs treated with FOLFOX adjuvant chemotherapy 
and 35 matched non-neoplastic mucosal tissues. CRC samples were classified into four 
molecular subtypes using nonnegative matrix factorization, and for comparison, we 
also grouped CRC samples using the proposed consensus molecular subtypes (CMSs). 
Of the 101 cases, 80 were classified into a CMS group, which shows a 79% correlation 
between the CMS classification and our four molecular subtypes. We found that two 
of our subtypes showed significantly higher disease-free survival and overall survival 
than the others. Group 2, in particular, which showed no disease recurrence or death, 
was characterized by high microsatellite instability (MSI-H, 6/21), abundant mucin 
production (12/21), and right-sided location (12/21); this group strongly correlated 
with CMS1 (microsatellite instability immune type). We further identified the molecular 
characteristics of each group and selected 10 potential biomarker genes from each. When 
these were compared to the previously reported molecular classifier genes, we found that 
31 out of 40 selected genes were matched with those previously reported. Our findings 
indicate that molecular classification can reveal specific molecular subtypes correlating 
with clinicopathologic features of CRCs and can have predictive value for the prognosis 
for stage III CRCs with FOLFOX adjuvant chemotherapy.
INTRODUCTION
Colorectal carcinomas (CRCs) have variable clinical, 
pathologic, and molecular features. Currently, these are 
classified based on the histologic findings, and tumor staging 
is determined by assessing spread at the time of diagnosis. 
Accurately determining the prognosis for individual patients 
with CRC is important, both for disease management, and 
for patient life planning. At present, prognosis is based 
predominantly on the pathologic stage of disease. However, 
formulating accurate projections for patients with stages 
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II and III cancer is difficult, due to the fact that these 
patients have intermediate survival rates, and predicting 
individual responses to adjuvant chemotherapy is currently 
impossible. For stage III CRCs, standard therapy involves 
curative surgery, followed by adjuvant chemotherapy 
with the FOLFOX regimen. However, no biomarkers or 
classification system for accurately determining prognoses 
after this chemotherapeutic regimen in stage III CRCs is 
available.
Gene expression-based subtyping is widely accepted 
as a relevant method for assessing disease stratification 
[1, 2]. Recently, an international consortium [3] was 
dedicated to network analysis of six previously published 
independent classifiers [2, 4-8] using Jaccard distance, 
Markov cluster (MCL) algorithm, and weighted silhouette 
width (R package ‘WeightedCluster’). Four consensus 
molecular subtypes (CMSs) of CRC were established with 
the following distinguishing features: CMS1 (microsatellite 
instability immune, 14%) indicative of hypermutations and 
microsatellite unstable features which generally accompany 
strong immune activation; CMS2 (canonical, 37%) 
showed epithelial characters and marked WNT and MYC 
signaling activation; CMS3 (metabolic, 13%) showed also 
epithelial characters and metabolic dysregulation; CMS4 
(mesenchymal, 23%) showed stromal infiltration, strong 
angiogenic features, and hyperactivation of transforming 
growth factors (TGF-β). Samples with mixed features 
(13%) were interpreted as a transition phenotype or 
represent an intratumoral heterogeneity [3].
Although these molecular subtypes can predict 
clinicopathologic characteristics and the natural prognosis 
of the disease, no gene expression-based subtyping 
system is available for calculating the prognoses of stage 
III CRCs after FOLFOX chemotherapeutic regimen. 
Specifically, evaluating the response to FOLFOX adjuvant 
chemotherapy according to molecular subtype may provide 
insights into 1) the natural course of stage III CRCs after 
FOLFOX chemotherapy according to molecular subtypes, 
and 2) the identification of specific subgroup(s) that most 
benefit from FOLFOX chemotherapy.
In this study, we selectively used fresh-frozen 
tissues of stage III CRCs treated with FOLFOX adjuvant 
chemotherapy. Homogeneous tumor cell population 
(> 70% tumor cells) of each tissue was collected by 
microdissection technique, which allowed us to minimize 
experimental error caused by differential proportion 
of tumor cells in tissue samples. We analyzed mRNA 
expression profiles of stage III CRCs samples and matched 
non-neoplastic colon mucosal tissues. In doing so, we 
identified colon cancer-specific transcripts and further 
found that CRC gene expression profiles can be divided 
into four types by nonnegative matrix factorization 
analysis. Moreover, we demonstrated an association 
between our specific molecular subtypes and the CMS, and 
further identified subtypes associated with good prognosis 
for stage III CRCs after FOLFOX chemotherapy.
RESULTS
Unsupervised clustering analysis of mRNA 
expression profiles identifies four distinct 
molecular subtypes
We first determined the mRNA expression profiles 
of 101 CRCs and 35 non-neoplastic colon mucosa tissue 
samples by microarray analysis, using the Human HT-12 
v4 Expression BeadChip, which contains 47,323 probes 
representing 31,332 annotated genes (Figure 1A). As 
a result, 4,823 genes were identified as differentially 
expressed genes (DEGs) that displayed a |fold change|>2 
and P-value<0.05 in colon cancers, as compared to 
non-neoplastic colon mucosa. To further analyze colon 
cancer-specific gene expression, we used unsupervised 
hierarchical clustering analysis of the 4,823 DEGs and 
found that CRC samples grouped into four separate 
clusters, distinct from the non-neoplastic colon mucosa 
tissues (Figure 1B). These gene expression microarray 
data have been deposited in NCBI’s Gene Expression 
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/
geo/) and are accessible through the GEO Series accession 
number GSE83889.
Gene expression-based molecular subtypes 
are categorized in four groups by nonnegative 
matrix factorization
To classify the 101 colorectal tumors according to 
the gene profiles of those tumors, we performed NMF 
consensus clustering using 1,764 tumor-specific DEGs 
that displayed a |fold change|>2 and P-value<0.01 in a 
more strict condition compared to non-neoplastic tissues. 
NMF is a nonnegative matrix factorization algorithm that 
focuses on the analysis of data matrices whose elements 
are nonnegative. To identify high consensus clusters 
(cophenetic coefficient, ρk, is closer to 1.0), we applied 
the various conditions for the factorization algorithm for 
each value of k cluster (k=2, 3, 4, 5, 6, and 7). We then 
obtained a consensus plot (and cophenetic coefficient) 
for each k=2 to 7 value and chose k values with high 
consensus. Using this consensus analysis with the 
1,764 DEGs, we found good consensus for k=4 clusters 
(coph=0.8961), suggesting that there was evidence for 
four consensus clusters (type 1) and hence, four functional 
distinct properties that can be elucidated from the DEGs 
of 101 colorectal tumors; group 1 (n=22, 21.8%), group 2 
(n=21, 20.8%), group 3 (n=16, 15.8%), and group 4 (n=42, 
41.6%) (Figure 2A). The consensus matrix showed that 
groups 1 and 4 appeared as individualized clusters (sharp 
consensus clustering), whereas groups 2 and 3 showed less 
distinct boundaries.
We also performed NMF consensus clustering with 
another selected gene set; the 1,538 DEGs that showed 
differential expression among tumor groups were divided 
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by the hierarchical clustering method (Figure 1B) when 
|fold change|>2 and P-value<0.01. In the NMF consensus 
analysis with these 1,538 DEGs, there are k=4 clusters 
(type 2) with high cophenetic coefficient (coph=0.8612); 
group 1 (n=20, 19.8%), group 2 (n=29, 28.7%), group 3 
(n=24, 23.8%), and group 4 (n=28, 27.7%) (Figure 2B). 
Samples represented in each group divided by NMF with 
either the 1,764 or the 1,538 DEGs were similar (77.2% 
matched).
In order to further characterize the gene expression 
of the different tumor subtypes, we analyzed expression 
patterns of 30 colon cancer classifier genes, known 
as the CRCassigner-30 [2], in four subtypes that were 
obtained each from type 1 and type 2 clustering under 
the conditions of |fold change|>1.5 and P-value<0.01 
(Figure 2C, 2D). In four tumor groups obtained from 
type 1 clustering, the expression of 5 genes was found to 
have increased in a specific tumor group, compared to the 
normal group (left panel of Figure 2C). In addition, the 
expression of 18 genes was found to have increased in a 
specific tumor group, compared to the rest of the tumor 
groups (right panel of Figure 2C). In four tumor groups 
obtained from type 2 clustering, the expression of two and 
17 genes was also found to have increased in a specific 
tumor group compared to the normal group or the rest of 
the tumor groups, respectively (Figure 2D). Overall, type 
1 clustering (NMF with 1,764 DEGs in tumors compared 
to non-neoplastic tissues) showed more distinct gene 
expression patterns between tumor groups than those 
of type 2 clustering (NMF with 1,538 DEGs in tumor 
groups divided by unsupervised hierarchical clustering). 
Therefore, we chose type 1 clustering for the subsequent 
gene expression analyses.
Clinicopathologic characteristics of CRCs 
according to molecular subtypes
We compared several clinicopathologic and 
molecular characteristics of our 101 CRCs according 
to the four molecular subtypes; the clinicopathologic 
characteristics of the samples in each of the four 
molecular subtypes are shown in Table 1. We found that 
there were several clinicopathologic parameters, showing 
significant differences in each group. Specifically, there 
are significant differences among the subtypes in tumor 
location (P<0.001), proportion of microsatellite instability 
(MSI) (P<0.001), presence of mucin (P<0.001), and 
incidence of KRAS mutation (P=0.01). Further, >50% of 
the cases in groups 3 (62.5%) and 4 (85.7%) presented 
as left-sided tumors. Conversely, >50% of the cases in 
groups 1 (54.5%) and 2 (57.1%) were located on the right 
side. Histologically, most cases were adenocarcinomas 
with moderate differentiation; there were four mucinous 
adenocarcinomas (mucin production in >50% of tumors) 
and two medullary carcinomas (carcinoma with prominent 
infiltration of intraepithelial lymphocytes). All four 
mucinous adenocarcinomas were in group 1, and the 
two medullary carcinomas were in group 2. In regards to 
extracellular mucin production, most cases in groups 3 
(87.5%) and 4 (92.9%) did not present with extracellular 
Figure 1: Workflow overview of gene expression-based molecular classification. (A) NMF consensus clustering using 1,764 
DEGs in tumors compared to non-neoplastic tissues. DEGs for each of the four groups, as compared to non-neoplastic colon mucosa tissues 
and/or the other groups were selected. DEG: differentially expressed genes, NMF: nonnegative matrix factorization. (B) Unsupervised 
hierarchical clustering analysis of mRNA expression profiles from colon cancer tissues. Unsupervised classification identifies four 
molecularly distinct subtypes. Red and green colors indicate transcript levels above and below the sample median, respectively. Complete 
separation of 35 normal colon tissues (red) and 101 colon cancers (sky blue) was evident based on gene expression profiles.
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mucin production; whereas, >50% of cases in groups 1 
and 2 showed extracellular mucin. We also found frequent 
KRAS mutations in group 1 (63.6%) and group 3 (56.3%) 
and less in groups 2 (28.6%) and 4 (26.2%). Further, we 
observed high MSI (MSI-H) in groups 2 (28.6%), and 1 
(9%), but no instances in groups 3 and 4.
Protein expression of the mismatch repair genes 
(MLH1, MSH2, PMS2, and MSH6) were then evaluated 
by immunohistochemistry. All six cases of MSI-H in 
group 2 showed loss of expression of MLH1 (five cases 
showed loss of MLH1 and PMS2 expression, and the 
remaining one case showed loss of MLH1, PMS2, and 
MSH6 expression). In contrast, one MSI-H case in group 
1 showed loss of expression of PMS2, and the other 
case showed loss expression of MSH2 and MSH6. One 
out of four mucinous adenocarcinomas was MSI-H, 
and both medullary carcinomas were MSI-H. Crohn’s-
like lymphoid reaction is a common feature of MSI in 
colon cancer, and therefore, this was evaluated using 
the Väyrynen-Mäkinen criteria. However, no significant 
differences were found between the different subtypes.
Correlation between our four molecular 
subtypes and the consensus molecular subtypes
We next employed ‘CMSclassifier’ (scripts and 
code for CMS classifier available at: https://github.com/
Sage-Bionetworks/crcsc) for CMS classification [2, 3] 
of our 101 CRC samples using k=4 clusters determined 
in Figure 2A. Among the 101 samples, 80 tumors were 
Figure 2: Four molecular subtypes identified using consensus clustering-based NMF. (A) NMF type 1 clustering: consensus 
clustering using 1,764 DEGs in tumors compared to non-neoplastic tissues. (B) NMF type 2 clustering: clustering with 1,538 DEGs 
specific for one group, as compared to other tumor groups. (C and D) Analysis of the mRNA expression patterns of the 30 genes from the 
CRCassigner-30 was performed according to each of the four subtypes from NMF type 1 clustering (C) and NMF type 2 clustering (D). 
NMF type 1 clustering showed more distinct gene expression patterns between the tumor subtypes than that of the NMF type 2 clustering.
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representative of each CMS; whereas, the remaining 21 
unlabeled samples (non-consensus samples) did not have 
any consistent pattern within the four CMS groups. When 
we compared the CMS grouping with our subtypes, and 
found that, of the 101 cancers, 63 showed close correlation 
to one of the four subtypes (Table 2). Specifically, 10 of 
21 group 2 samples were included in CMS1 (microsatellite 
instability immune and characterized as hypermutated, 
microsatellite unstable and strong immune activation), and 
all 10 that grouped in CMS1 were also classified in group 
Table 1: Clinical and pathologic features of each molecular group
Category Variables Group 1 Group 2 Group 3 Group 4 P-value
(n=22, 21.8%) (n=21, 20.8%) (n=16, 15.8%) (n=42, 41.6%)
Age, years 57.95±13.26 58.09±13.67 62±9.04 58.81±9.42 0.802
Gender Male 14 63.6% 8 38.1% 7 43.8% 22 52.4% 0.376
Female 8 36.4% 13 61.9% 9 56.2% 20 47.6%
Location Right side 12 54.5% 12 57.1% 6 37.5% 6 14.3% <0.001a
Left side 10 45.5% 9 42.9% 10 62.5% 36 85.7%
Preop CEA level ≤5 ng/ml 18 81.8% 17 81.0% 10 62.5% 28 66.7% 0.367
>5 ng/ml 4 18.2% 4 19.0% 6 37.5% 14 33.3%
Histologic 
diagnosis Adenocarcinoma 18 81.8% 19 90.5% 16 100.0% 42 100.0% <0.001
a
Mucinous 
adenocarcinoma 4 18.2% 0 0.0% 0 0.0% 0 0.0%
Medullary 
carcinoma 0 0.0% 2 9.5% 0 0.0% 0 0.0%
Mucin formation Absent 10 45.5% 9 42.8% 14 87.5% 39 92.9% 0a
Focal 8 36.4% 12 57.2% 2 12.5% 3 7.1%





group 14 63.6% 13 61.9% 8 50.0% 33 78.6% 0.157
high-density 
group 8 36.4% 8 38.1% 8 50.0% 9 21.4%
invasion pattern expending 2 9.1% 7 33.3% 2 12.5% 4 9.5% 0.098
infiltrative 20 90.9% 14 66.7% 14 87.5% 38 90.5%
BRAFb Wild type 22 100.0% 20 95.2% 16 100.0% 42 100.0% 0.366
Mutation 0 0.0% 1 4.8% 0 0.0% 0 0.0%
KRASb Wild type 8 36.4% 15 71.4% 7 43.8% 31 73.8% 0.01a
Mutation 14 63.6% 6 28.6% 9 56.3% 11 26.2%
MSI status MSS/ MSI-low 20 90.9% 15 71.4% 16 100.0% 42 100.0% <0.001a
MSI-high 2 9.0% 6 28.6% 0 0.0% 0 0.0%
MLH1 lossc 0 6 0 0
MSH2 lossc 1 1 0 0
PMS2 lossc 1 5 0 0
MSH6 lossc 1 1 0 0
aP<0.05, bPyrosequencing, cImmunohistochemical stain, MSS: Microsatellite stability, MSI: Microsatellite instability
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2. Both the group 2 and CMS1 samples were characterized 
by frequent MSI-H tumors. Similarly, 31 out of 42 
samples from group 4 were classified as CMS2 (canonical 
and characterized by marked WNT and MYC signaling 
activation), while 31 out of 38 samples in CMS2 also 
were found in group 4. These group 4 and CMS2 types 
are characterized by frequent left-sided preponderance. 
We further observed that 12 out of 22 group 1 samples 
were classified as CMS3 (metabolic and characterized by 
evident metabolic dysregulation), and 12 out of 13 CMS3 
cases belonged to group 1. In our study, 13 (13%) of CMS3 
cases were characterized by high KRAS mutation rates. 
Finally, we found that 10 out of 16 samples belonging 
to group 3 were classified into CMS4 (mesenchymal and 
characterized by prominent transforming growth factor 
activation, stromal invasion and angiogenesis), while 
10 out of 19 CMS4 samples also belonged to group 3. 
When we exclude the 21 non-consensus cases, a 79% 
(63 out of 80 cases) correlation was found between the 
CMS classification and our molecular classification. The 
distribution of the CMS groups is shown in Table 2.
To evaluate how well NMF consensus clustering 
matched CMS classification, we further performed 
subtyping analysis by using the same set of samples used 
for NMF consensus clustering by another commonly used 
subtyping method that combines Euclidean distance, 
Ward’s minimum variance method, and weighted gene 
co-expression network analysis (WGCNA). This analysis 
showed that 101 CRCs were divided into four main groups 
(group A-D), and all groups well-matched only CMS2 and 
not the remaining CMS subtypes (Supplementary Table 1). 
With the highest concordance rates, 13 out of 38 samples 
of group A, 14 out of 26 samples of group B, and half 
of 10 samples of group C belonged to CMS2. In group 
D, 6 out of 27 samples belonged to CMS2 or CMS4, 
respectively. These results showed that NMF consensus 
clustering was a highly compatible classification method 
to CMS classification.
We further compared several clinicopathologic and 
molecular characteristics of our 101 CRCs according 
to the CMS molecular subtypes. The clinicopathologic 
characteristics of four CMS molecular subtypes and 
non-consensus subtypes are shown in Supplementary 
Table 2. As expected, similar clinicopathologic parameters 
were found to vary according to both our classification 
system and the CMS grouping. There are significant 
differences among the subtypes in tumor location 
(P<0.01), proportion of MSI-H tumors (P<0.001), 
presence of mucin (P<0.001), and incidence of KRAS 
mutation (P<0.05). Cases classified as CMS1 displayed 
a right-sided preponderance (>70%), exophytic growth 
pattern, normal preoperative CEA level, and high 
preponderance of MSI-H tumors. In contrast, CMS2 cases 
a showed left-sided preponderance (84.2%) and frequent 
(31.6%) increased preoperative CEA level. Additionally, 
>50% of cases in CMS3 showed extracellular mucin 
production and frequent (61.5%) KRAS mutation.
Patient survival according to molecular subtype
We performed a survival analysis on the 101 CRC 
patients according to the molecular subtypes. The mean 
follow-up time was 57.8 months (ranging from 15 to 115 
months). With follow up, 13 patients (12.9%) relapsed, and 
six (5.9%) died from colon cancer-related causes. Groups 
2 and 3 showed significantly better overall survival (OS) 
(P=0.019) than groups 1 and 4, which indicates that group 
2 and 3 are associated with favorable prognosis (Figure 
3A, 3B). We further performed survival analysis using a 
separate set of group 1, 2, and 3, and another set of group 
2, 3, and 4, respectively. Groups 2 and 3 showed better 
disease-free survival (DFS) (P=0.039) and OS (P=0.027) 
than group 1, but not group 4 (Supplementary Figure 1). 
In consistent with these findings, the two subtypes from 
the CMS classification showing high concordance rates in 
overall survival were CMS1 and CMS4, which correspond 
to our groups 2 and 3, respectively (Figure 3C, 3D).
Identification of differentially expressed genes in 
each molecular subtype
We further analyzed gene expression patterns, 
in order to identify gene subsets that are differentially 
expressed in the four groups, as compared to neoplastic 
Table 2: Correlation between 4 molecular groups and CMS subtypes
NMF network class Total
Group 2 Group 4 Group 1 Group 3
Predicted CMS class CMS1 10 (66.6%) 0 (0%) 0 (0%) 0 (0%) 10
CMS2 4 (26.7%) 31 (79.5%) 3 (18.8%) 0 (0%) 38
CMS3 1 (6.7%) 0 (0%) 12 (75%) 0 (0%) 13
CMS4 0 (0%) 8 (20.5%) 1 (6.2%) 10 (100%) 19
undetermined 6 3 6 6 21
Total 21 42 22 16 101
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colon mucosa tissues and/or other groups. Differently 
expressed genes were identified in each group: 194 genes 
in group 1,736 genes in group 2,493 genes in group 3, and 
634 genes in group 4. In addition, 275 genes, 372 genes, 
558 genes, and 184 genes were differentially expressed in 
each respective group, as compared to the other groups 
(Figure 4A). We next selected genes that are characteristic 
of each group by choosing those that are differentially 
regulated as compared to both normal tissue and the 
other molecular groups. As a result, 292 genes were 
found as potential group markers (Figure 4A, 4B). We 
finally selected ten genes from this group genes that are 
overexpressed >1.5-fold in one group, as compared to both 
normal tissues and tumors in other groups. Among these 
genes, especially, DEFA5, DUOX2, KLK12, and ALDOB 
in group 1, CCDC58, MOCOS, and FAM81A in group 
2, HOPX, TAGLN, GREM1, THBS4, COL3A1, PRRX1, 
RAB31, MYL9, CTSK, and SPARC in group 3, and DSC3 
and CAB39L in group 4 were up-regulated (>2.0-fold) 
(Figure 4C, Table 3).
We next performed survival analysis according to 
the expression of two randomly selected genes out of 
10 genes that represented characteristic of each group. 
Although statistically insignificant in some genes, there 
was a trend where cases were distinctively divided 
into poor and good prognosis groups according to the 
expression of selected gene (Supplementary Figure 2). 
High expression of KLK12 and MUC5AC (group 1), and 
DSC3 (group 4) was associated with poor prognosis, while 
high expression of FAM81A, SEH1L, TAGLN and THBS4 
(group 2 and 3), and TSPAN6 (group 4) was associated 
with good prognosis.
Figure 3: Patient survival rate analysis according to our CRC molecular subtype and the CMS. (A and B) Disease-free 
survival and overall survival according to our four molecular subtypes. (C and D) Disease-free survival and overall survival according to 
the four CMS subtypes.
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DISCUSSION
The identification of predictive biomarkers and the 
development of a molecular classification that can predict 
therapeutic responses of advanced CRCs are major goals 
in cancer research. A number of recent studies have 
elucidated several molecular CRC subtypes by gene 
expression profiling, and some of these have been reported 
to be associated with specific clinical outcomes [2, 4–8]. 
For example, Budinska et al. [4] divided CRCs into five 
subtypes, and demonstrated that one was associated with 
good outcomes (designated as lower crypt subtype) and 
another with poor outcomes (designated as mesenchymal 
subtype). Marisa et al. [5] outlined six CRC subtypes 
and found that one (designated as cancer stem cell and 
CIN normal subtype) was related to poor prognosis. 
Roepman et al. [7] proposed three subtypes, one of which 
(designated as the A subtype) was characterized by right-
sided preponderance, was hypermutated with frequent 
MSI and BRAF mutations, and was associated with a 
good prognosis. De Sousa et al. [6] also divided CRCs 
into three molecular subtypes and found one (designated 
as CCS3 subtype) was related to poor differentiation 
and associated with poor prognosis. Sadanandam 
et al. [2] proposed five molecular subtypes, one of which 
(designated as stem-like subtype) was related to poor 
Figure 4: Identification of mRNAs differentially expressed in each of the four groups, as compared to non-neoplastic 
colon mucosa tissues and/or the other groups. (A) Venn diagram showing a total of 292 potential marker genes, with group specific 
upregulation. (B) Heatmap of the mRNA expression profiles of these 292 DEGs according to the four molecular groups. (C) The mRNA 
expression profiles of 10 selected genes from each group.
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Table 3: Specific-upregulated genes in each molecular group
Gene cluster Gene symbola Description FC. T vs. N FC. Specific T 
group vs. other 
T groups
Group 1 DEFA5 defensin, alpha 5, Paneth cell-specific 4.56 4.65
DUOX2 dual oxidase 2 4.28 3.91
KLK12 kallikrein-related peptidase 12 3.19 2.77
ALDOB aldolase B 5.37 2.61
GABRP gamma-aminobutyric acid (GABA) A receptor, 
pi
1.84 1.95
LOC653061 similar to Golgin subfamily A member 8-like 
protein 1
2.62 1.95
APOBEC1 apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide 1
3.31 1.88
C2CD4B family with sequence similarity 148, member B 2.93 1.82
MUC5AC mucin 5AC, oligomeric mucus/gel-forming; 
similar to hCG1778310
2.27 1.79
SEZ6L2 seizure related 6 homolog (mouse)-like 2 2.35 1.73
Group 2 CCDC58 coiled-coil domain containing 58 6.19 2.81
MOCOS molybdenum cofactor sulfurase 2.92 2.11
FAM81A family with sequence similarity 81, member A 2.59 2.06
MTHFD2 methylenetetrahydrofolate 
dehydrogenase (NADP+ dependent)2, 
methenyltetrahydrofolate cyclohydrolase
3.10 1.99
SLC7A11 solute carrier family 7, (cationic amino acid 
transporter, y+ system) member 11
2.52 1.93
PBK PDZ binding kinase 2.78 1.91
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 3.49 1.90
LDHB lactate dehydrogenase B 3.18 1.86
SEH1L SEH1-like (S. cerevisiae) 2.14 1.83
CDCA2 cell division cycle associated 2 2.38 1.77
Group 3 HOPX HOP homeobox 4.26 4.11
TAGLN Transgelin 2.66 3.73
GREM1 gremlin 1 2.12 3.59
THBS4 thrombospondin 4 2.85 3.58
COL3A1 collagen, type III, alpha 1 5.33 3.34
PRRX1 paired related homeobox 1 4.29 3.23
RAB31 RAB31, member RAS oncogene family 3.60 3.21
MYL9 myosin, light chain 9, regulatory 2.38 3.13
CTSK cathepsin K 2.59 3.11





prognosis, and similarly, Schlicker et al. [8] identified five 
CRC subtypes, and found one (designated as 1.1 subtype) 
was related to poor prognosis and another (designated 
as 2.1 subtype) that was associated with better DFS. To 
comprehensively understand molecular CRC subtypes, 
we further matched these independently reported CRC 
subtypes to CMS subtypes. In Budinska et al.’s study [4], 
lower crypt subtype was associated with good outcomes, 
CIMP subtype was associated with worse survival after 
relapse, and mesenchymal subtype with worse relapse-
free survival and overall survival. These three subtypes 
corresponded to CMS2, CMS1, and CMS4, respectively. 
Other subtypes such as cancer stem cell subtype (Marisa 
et al.) [5], C subtype (Roepman et al.) [7], CCS3 subtype 
(De Sousa et al.) [6], stem-like subtype (Sadanandam 
et al.) [2], and 1.1 subtype (Schlicker et al.) [8] were 
commonly related to worse relapse-free survival and 
overall survival, and these subtypes generally matched 
CMS4. These previously reported molecular subtypes 
were also associated with the characteristics of our 
groups. The KRAS-mutated subtype [5] is related to our 
group 1, whereas our group 2 is similar to the dMMR 
[5], A type [7] and CCS2 [6] subtypes, all of which are 
more commonly located in the right side of the colon and 
contain high MSI [9]. We further observed that our group 
3 shares characteristics with the 1.3 subtype [8], which 
contains microsatellite stability (MSS) and activated 
transporter genes, and further, group 4 is associated with 
the B subtype [7], which is most commonly found in the 
left side of the colon.
The reported molecular classifications all have 
potential for both prognosis evaluation and for predicting 
the therapeutic responses of advanced CRCs. However, 
we believe that the previously reported molecular 
classification systems have several features limiting 
their clinical utility. Specifically, many of the published 
studies have a diverse clinical cohort, as well as non-
uniform sources for clinical sample acquisition (e.g., RNA 
extraction from fresh-frozen samples or from formalin-
fixed paraffin-embedded samples). Further, experimental 
methodological differences and distinct data processing 
algorithms may produce discrepant results. Therefore, 
in order to establish a collaborative subtyping for CRC 
and to resolve inconsistencies among the reported gene 
expression-based CRCs, four CMSs with distinguishing 
features were proposed by an international consortium 
[3]. By this CMS classification, 80 out of 101 cases 
analyzed in our study were classified into one of the 
four groups, whereas 21 cases were not categorized 
and thus placed in the non-consensus group. Here, 
we performed NMF consensus clustering with 1,764 
DEGs in tumors compared to non-neoplastic tissues and 
identified four CRC molecular subtypes. We found close 
correlation between group 2 and CMS1 (microsatellite 
instability immune), group 4 and CMS2 (canonical), 
group 1 and CMS3 (metabolic), and group 3 and CMS4 
(mesenchymal).
Although each of our molecular subtypes generally 
matched to a specific CMS, and they showed similarities 
to the CMS system, there are also some critical 
differences. Specifically, our molecular grouping method 
divided all 101 CRC cases into one of the four groups, 
whereas 21 cases were not categorized using the CMS 
system. Of the remaining 80 cases that were classified 
by the CMS, 79% were grouped in a correlating subtype. 
Therefore, 63% of the 101 cases were completely 
Gene cluster Gene symbola Description FC. T vs. N FC. Specific T 
group vs. other 
T groups
Group 4 DSC3 desmocollin 3 2.66 2.21
CAB39L calcium binding protein 39-like 2.22 2.07
ASXL1 additional sex combs like 1 (Drosophila) 1.99 1.80
ERP27 endoplasmic reticulum protein 27 2.55 1.70
ZMYND8 zinc finger, MYND-type containing 8 1.90 1.69
ACSL6 acyl-CoA synthetase long-chain family member 
6
1.94 1.67
GMEB2 glucocorticoid modulatory element binding 
protein 2
1.78 1.66
HPDL 4-hydroxyphenylpyruvate dioxygenase-like 2.79 1.66
TSPAN6 tetraspanin 6 2.11 1.64
C8orf33 chromosome 8 open reading frame 33 2.15 1.63
aSelected genes that show specific-upregulated expression in each molecular group. Those matching previously reported 
classifier genes are marked in bold.
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matched in both systems. Since we evaluated the 
predictive value of molecular classification using only 
stage III CRCs with FOLFOX adjuvant chemotherapy 
and performed microdissection of each fresh-frozen 
sample, we believe that our approach enabled the 
analysis of homogeneous tumor cell populations (>70% 
tumor cells); therefore, experimental errors from 
different tumor populations were minimalized. We rather 
suspect that the discrepant results might result from the 
diverse patient cohorts, sample preparation methods, and 
different technologies utilized for the analysis of gene 
expression platforms.
Our NMF consensus clustering-based molecular 
classification showed that patients in groups 2 and 3 
exhibited a significant advantage in overall survival 
(P=0.019), as well as a trend toward better DFS (P=0.104). 
More specifically, survival analysis using groups 1, 2, and 
3 revealed that patients in groups 2 and 3 showed better 
DFS (P=0.039) and OS (P=0.027) than group 1, but no 
significant difference in survival was observed when we 
analyzed groups 2, 3 and 4. Supporting these findings, a 
previous report showed that stages II and III CRC patients 
with good prognosis could be categorized into a subtype 
highly similar to group 2, with features such as MSI, 
BRAF mutations, and right-sided tumor location [5–7]. 
Moreover, the overall survival curve for our patients based 
on CMS subtype showed a worse outcome for CMS2 and 
CMS3, which correlate to groups 4 and 1, respectively, in 
our study. However, statistical significance was not found 
in the CMS classification, likely due to small number of 
cases that were classified. These findings suggest that our 
molecular classification can identify homogeneous subsets 
of stage III CRCs with either a good or bad prognosis after 
FOLFOX adjuvant chemotherapy. We note, however, 
that we could not conclude that the clinical results from 
the patients with good prognosis subtypes can predict 
responses to the FOLFOX regimen or the natural clinical 
disease course, as this was not a prospective study. To 
better predict responses to FOLFOX adjuvant therapy, 
a large cohort including CRC mucosa tissues without 
FOLFOX adjuvant chemotherapy should be included in 
future study.
We analyzed the molecular characteristics of each 
subtype by performing gene ontology analysis with the 
differentially expressed subtype-specific genes. This 
revealed that the expression of cell death and apoptosis 
genes were lower in group 1 tumors. It has previously 
been reported that the important functional consequence 
of CRCs with a KRAS mutation is lack of apoptosis, 
and 14 out of 22 CRCs in group 1 had a KRAS mutation 
[10, 11]. In group 2, increased expression of genes 
associated with p53 signaling and cell proliferation was 
noted, and six out of eight MSI-H CRCs were classified 
in this group. MSI-H tumors are known to have a 
more favorable prognosis than the MSS/MSI-L CRCs. 
Further, it has been reported that increased expression 
of p53 is associated with good survival outcome 
in the stage III CRCs with FOLFOX therapy [12]. 
Accordingly, the group 2 CRCs in our study showed 
the best survival after FOLFOX therapy. In group 3 
CRCs, expression of genes associated with inhibition 
of epithelial-to-mesenchymal transition was increased, 
whereas genes associated with fatty acid synthesis 
and the TCA cycle were decreased. The association 
between decreased expression of metabolic genes and 
good prognosis had been reported in both CRC and 
hepatocellular carcinoma [13, 14], and agreement with 
this, CRC patients in group 3 showed a better prognosis 
than those in the other groups. In group 4 CRCs, 
decreased expression of genes associated with antigen 
processing and presentation and immune response was 
observed, and this has previously been associated with a 
poor prognosis in many cancers [15–21]. In agreement 
with this, the prognosis for group 4 CRCs was the worst 
of any of the groups in our study.
We further selected 10 potential biomarker genes 
from each group by identifying the genes that were 
differentially expressed both between the tumor groups 
and normal mucosa. We then compared these genes 
to those selected as a molecular classifier in a number 
of previously published papers [2, 4–8]. We found 
that >50% of our genes matched previously reported 
classifier genes (comprised of a total of 2032 genes from 
six different studies). In group 1, six genes [DEFA5 
(4.56/4.65-fold), DUOX2 (4.28/3.91-fold), KLK12 
(3.19/2.77-fold), GABRP (1.84/1.95-fold), APOBEC1 
(3.31/1.88-fold), and MUC5AC (2.27/1.79-fold)] 
matched previously reported genes. Of these, DEFA5 
had been shown to be a key factor in the formation of 
adenomas, and has been proposed as a prognostic and 
predictive potential molecular biomarker in CRCs [22]. 
In group 2, three genes [MOCOS (2.92/2.11-fold), 
SLC7A11 (2.52/1.93-fold) and PBK (2.78/1.91-fold)] 
matched previously reported genes. The over-expression 
of SLC7A11, a p53-associated gene, had been shown to 
have an important role in tumor growth suppression [23]. 
In group 3 CRCs, all 10 genes (HOPX, TAGLN, GREM1, 
THBS4, COL3A1, PRRX1, RAB31, MYL9, CTSK and 
SPARC) matched the previously reported molecular 
classifier [2, 4–8], and most of these genes were known 
to function as suppressors during EMT process. HOPX 
(4.26/4.11-fold) is a known colon stem cell marker and is 
associated with the suppression of tumor metastasis [24], 
and TAGLN (2.66/3.73-fold) was found as a novel tumor 
suppressor and its post-surgical high expression was 
reported to be associated with good prognosis in stage III 
CRCs [25]. GREM1 (2.12/3.59-fold) was reported to be 
closely associated with low lymphovascular invasion and 
good prognosis in locally advanced stage II and III CRCs 
[26]. In group 4, five genes genes [CAB39L (2.22/2.07-
fold), ASXL1 (1.99/1.80-fold), ERP27 (2.55/1.70-fold), 
ACSL6 (1.94/1.67-fold), and TSPAN6 (2.11/1.64-fold)] 
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matched previously reported classifier genes, and of 
these, TSPAN6 was the most frequently reported in the 
six previous papers. TSPAN6 has been associated with 
tumor cell migration [27, 28], and over-expression is 
linked to worsened survival in CRC patients. We further 
matched our potential biomarker genes to classifier genes 
provided from a recently reported study, which merged 
and evaluated 22 types of previously reported classifiers 
[29]. Overall, about 80 % of our potential biomarker 
genes overlapped with classifier genes reported by 22 
different previous studies. These findings indicate that 
our genes may serve as clinically useful molecular 
biomarkers for tumor classification.
Collectively, these findings suggest that molecular 
classification using these molecular markers may be 
possible, and future prospective studies may further 
elucidate their prognostic and predictive values for 
assessing the response to FOLFOX adjuvant therapy in 
stage III CRCs.
MATERIALS AND METHODS
Patients and tumor tissues
A total of 101 CRCs and 35 matched non-neoplastic 
colon mucosal tissue samples were analyzed in this study. 
All the cancers were stage III (metastasis to regional 
lymph nodes but not to distant sites) and were treated 
with the FOLFOX regimen; none of the patients had 
received neo-adjuvant chemotherapy. The specimens 
were obtained from the archives of the Department of 
Pathology, Yonsei University, Seoul, Korea and from the 
Liver Cancer Specimen Bank of the National Research 
Resource Bank Program of the Korean Science and 
Engineering Foundation of the Ministry of Science and 
Technology. Information from the tumor registry and chart 
review data were obtained to determine demographics, 
tumor site, and follow up. The population contained 50 
females and 51 males. The 36 tumors located proximal to 
the splenic flexure were classified as right-sided and the 
65 distal to the splenic flexure as left-sided. Patient data 
were collected retrospectively. All patients had undergone 
curative colorectal resection between 2006 and 2012, and 
fresh snap-frozen samples were obtained immediately at 
the time of surgery. Tumor specimens were microdissected 
using a cryostat and fractionated to improve tumor content. 
Briefly, prior to cutting sections for RNA isolation, a slide 
was prepared for hematoxylin-eosin staining to allow the 
selection of samples with >70% tumor cells; samples with 
a tumor cell content <70% were further cut to enrich the 
tumor cell population. Through this process, were ensured 
that all carcinoma samples analyzed in this study were 
comprised of >70% tumor cells. Authorization for use of 
these tissues for research purposes was obtained from the 
Institutional Review Board of the Yonsei University of 
College of Medicine.
RNA preparation
Total RNA was extracted using TRIzol Reagent 
(Invitrogen Life Technologies, Carlsbad, CA, USA), 
according to the manufacturer’s protocol. After DNase 
digestion and other clean-up procedures, RNA samples 
were quantified, aliquoted, and stored at -80°C until 
use. For quality control, RNA purity and integrity 
were evaluated by denaturing gel electrophoresis and 
measurement of the A260/280 ratio, and all samples 
were analyzed using the 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, USA). For all samples, 
the RNA integrity number scores were >9.5.
Gene expression analysis
For DNA microarray hybridization, RNA was 
pooled by mixing equal amounts of total RNA, and 
biotin-labeled cRNA targets were synthesized starting 
from 1.5 μg of total RNA. Double-stranded cDNA 
synthesis was performed using the Illumina® TotalPrep 
RNA Amplification Kit (Illumina, San Diego, CA, USA), 
while biotin-UTP-labeled antisense RNA was transcribed 
in vitro using the Ambion MEGAscript kit (Ambion 
Life Technologies, Carlsbad, CA, USA). All steps of 
the labeling procedure were performed according to the 
manufacturers’ protocols. Microarray experiments were 
conducted on the HumanHT-12 v4 Sentrix Expression 
BeadChip (Illumina), which contains 47,231 probes, 
representing 31,332 annotated genes. Hybridization of 
labeled cRNA to the BeadChip, washing, and scanning 
were performed according to the Illumina Bead Station 
500× manual.
mRNA gene expression data preparation and 
statistical analysis
Raw data were extracted using the software provided 
by the manufacturer (Illumina Genome Studio v2011.1 
[Gene Expression Module v1.9.0]), and expression 
intensities were normalized using quantile normalization 
techniques [30]. Based on these normalized intensities, 
genes differentially expressed in non-neoplastic colon 
mucosal tissues and in colon tumors were determined 
using the integrated statistical method previously reported 
[31]. Briefly, 1) two independent tests were performed: 
a Student’s t-test and the log2-median-ratio test; 2) 
adjusted P-values from each test were computed using 
an empirical distribution of the null hypothesis that the 
means of the genes are not different, which was obtained 
from random permutations of the samples; 3) the P-
values from the two tests were combined to compute the 
overall P-values using Stouffer’s method [32], and 4) For 
unsupervised hierarchical clustering in Figure 1B, 4,823 
DEGs were selected from the microarray raw data under 
the conditions of |fold change|>2 and P-value<0.05. For 
NMF consensus clustering analysis in Figure 2A, 1,764 
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DEGs were selected from the microarray raw data under 
the conditions of |fold change|>2 and P-value<0.01. For 
NMF consensus clustering analysis in Figure 2B, 1,538 
DEGs were selected from DEGs among tumor groups 
that were divided by unsupervised hierarchical clustering 
under the conditions of |fold change|>2 and P-value<0.01. 
For gene expression analysis in Figure 2C and 2D, |fold 
change|>1.5 and P-value<0.01 were applied to obtain 
DEGs belonging to CRCassigner-30, which was a group 
of 30 genes with high scores calculated by PAM (nearest 
shrunken centroids–based method) [33] reported in a 
previous study [2]. Finally, functional enrichment analysis 
of the differentially expressed genes was performed using 
DAVID software [34], in order to identify GO biological 
processes and Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways represented by the genes in individual 
clusters with statistical significance.
Molecular subtyping and comparison to 
published consensus molecular subtype
For molecular subtyping, we applied a hierarchical 
clustering and nonnegative matrix factorization (NMF) 
[35–37], using the gene expression profiles from CRC 
tissues. In brief, NMF consensus clustering method 
resorts to factor the gene-expression matrix A into the 
product of two matrices of positive entries, A ∼ WH. 
Matrix W has size N × k and Matrix H has size k × M. 
k is much smaller than M. The column of W defines 
a ‘metagene’, with entry wij the coefficient of gene i 
in metagene j. The columns of Matrix H represent 
metagene expression pattern of the corresponding 
sample, with each entry hij representing the expression 
level of metagene i in sample j. Given factorization 
of A ∼ WH, Matrix H can be used to determine the 
cluster membership: sample j is placed in cluster 
i if the hij is the largest entry in column j [35]. 
Differentially expressed genes were selected using 
complete linkage for hierarchical clustering based 
on the Pearson coefficient correlation algorithm, and 
these were utilized for NMF with MATLAB software. 
Molecular subtyping was performed with consensus 
clustering-based NMF, according to the optimal 
number of clusters, which was determined based on the 
cophenetic correlation coefficient (coph) values [37, 38] 
determined in our previous study (coph=0.8961). We 
performed a repeated NMF clustering analysis using the 
same set of samples with 1,764 DEGs under the same 
condition, and confirmed that the four groups divided 
by type 1 clustering were reproducible (93% matched). 
To subtype our samples by another method, we adopted 
Ward’s minimum variance method in combination with 
Euclidean distance and weighted gene co-expression 
network analysis (WGCNA) [39]. WGCNA was used 
to verify the quality of our microarray data, and Ward’s 
minimum variance method according to Euclidean 
distance was used to cluster 101 colorectal tumors. To 
compare our molecular subtypes with the previously 
reported CMSs, we used CMSclassifier [3], which 
includes the random forest classifier, as well as a 
‘single-sample predictor’ (SSP) classifier. Further, the 
prognosis predicting values of our molecular subtypes 
and CMS subtypes were compared and analyzed by 
‘CMSclassifier’.
KRAS and BRAF mutation analysis
KRAS mutation analysis was performed via 
pyrosequencing, using the CE-IVD Marked PyroMark 
KRAS Kit (QIAGEN, Hilden, Germany), according 
to the manufacture’s protocols (Therascreen KRAS 
Pyro Kit Handbook, version 1, July 2011). For each 
sample, 10 ng of genomic DNA was used for analysis 
of mutations in codons 12 and 13 and another 10 ng 
DNA was utilized to identify mutations in codon 61. 
Pyrosequencing was also employed for BRAF mutation 
analysis to detect the BRAF V600E mutation, as 
previously reported [40].
Immunohistochemistry
Paraffin-embedded tissue blocks were cut into 
4-μm sections. Immunohistochemical analysis was 
performed using a Ventana XT automated stainer (Ventana 
Corporation, Tucson, AZ, USA) with antibodies against 
the following: MutL homolog 1 (MLH1, diluted 1:50, 
BD Biosciences, San Jose, CA, USA), MutS homolog 2 
(MSH2, diluted 1:200, BD Biosciences), MutS homolog 
6 (MSH6, diluted 1:300, Cell Signaling Technology, 
Beverly, MA, USA), and PMS1 homolog 2 (PMS2, 
diluted 1:40, Cell Marque, Rocklin, CA, USA).
Analysis of clinical and pathological parameters
All statistical analyses were performed using SPSS 
software, version 21.0.0.0 for Windows (SPSS Inc., 
Chicago, IL, USA). To analyze each clinicopathological 
parameter, the Kruskal-Wallis test, Mann-Whitney test, 
Fisher’s exact test, or the χ2-test were used, depending 
on the purpose; all P-values <0.05 were considered 
significant. Patient survival statistics were analyzed 
using the Kaplan-Meier method and log-rank test, and 
multivariate analyses were performed using the Cox 
regression model. Hazard ratios (HRs) and corresponding 
95% confidence intervals (CIs) are presented.
Abbreviations
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